Journal of Clinical Oncology

Vol. 44, Issue 16_suppl Issue 16_suppl 2026
7213
Articles

Articles in this Issue

Association between physical disability status and up-to-date colorectal cancer screening: A cross-sectional study.

Kallyn Bravo, Teana Tee, Cara Gillespie et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13747

e13747 Background: Colon cancer is the second most common cause of cancer death in men and women combined, with an estimat...

Prognostic value of androgen receptor (AR) in breast cancer: A systematic review.

Mohamed Yasin, Hiba Noor, Anmol Singh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e12762

e12762 Background: The androgen receptor (AR) is a potential therapeutic target for breast cancer (BC). Nonetheless, the u...

A phase 2 randomized trial of radium-223 dichloride and cabozantinib in patients (pts) with renal cell carcinoma (RCC) with bone metastases (BM): RADICAL (Alliance A031801).

Rana R. McKay, Pamela J. Atherton, Karla V. Ballman et al. Jun 01, 2026 pp. 4500-4500 10.1200/jco.2026.44.16_suppl.4500

4500 Background: BM occur in ~30% of RCC pts and are associated with poor survival and symptomatic skeletal events...

Metastatic phenotype at diagnosis for prediction of survival in de novo stage IV neuroendocrine carcinoma of the breast: A SEER Research Plus analysis.

Maryam Ali, Syed Musharraf Shah, Abdulmalek Aljafari et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13106

e13106 Background: Neuroendocrine carcinoma of the breast (NECB) is a rare malignancy, and population-level data describin...

Urokinase gene knockout and melanoma mitochondria: Association with free radical oxidation processes.

Galina G. Beloshapkina, Irina Valerevna Neskubina, Elena M. Frantsiyants et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21535

e21535 Background: Mitochondria play a key role in carcinogenesis, and an imbalance in the oxidant-antioxidant system infl...

In silico phase III clinical trial of avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma using a machine learning model transfer approach.

Zuhair Majeed, Peng Li, Claire F. Verschraegen et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16500

e16500 Background: Randomized clinical trials (RCTs) are the gold standard for establishing treatment benefit, but...

A prediction nomogram for perioperative deep vein thrombosis risk in breast cancer patients: A retrospective cohort study with prospective clinical application.

Zhenchuan Song, Tianjiao Ge, Meiqi Wang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e13541

e13541 Background: Deep vein thrombosis (DVT) represents a prevalent postoperative complication among breast cancer periop...

Risk evaluation and mitigation strategies for approved oncology drug and non-cellular biologic products from 2008 to 2025: An FDA analysis.

Oladimeji Akinboro, Abhilasha Nair, Laura Zendel et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e23029

e23029 Background: The Food and Drug Administration Amendments Act of 2007 (FDAAA) granted FDA the authority to require Ri...

Biomarker testing patterns and patient outcomes for metastatic NSCLC, CRC, and metastatic/recurrent HNSCC at Texas Oncology.

Ayda Mirsalehi, Tracy Li, Hozefa Divan et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20661

e20661 Background: Biomarker testing is essential for selecting targeted and immunotherapy regimens in non–small cell lung...

Real-world outcomes of first-line lenvatinib versus sorafenib in advanced HCC.

Ahmad Al-Alwan, Mohammed Aloqaily, Mrinalini Ramesh et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16228

e16228 Background: Lenvatinib and sorafenib are approved first-line tyrosine kinase inhibitors for patients with unresecta...

Burnout (BO) among oncology professionals in the Middle East and North Africa (MENA): Meta-analysis of pre–post COVID trends, contributors, and predictive value of single-item screening tool.

Atlal M. Abusanad, Bashar Hasan, Khalid Jazieh Jun 01, 2026 pp. 9010-9010 10.1200/jco.2026.44.16_suppl.9010

9010 Background: BO among oncology professionals is prevalent and may have changed following the COVID-19 pandemic. We con...

Assessing the clinical utility of MRI for preoperative staging of early-stage cervical cancer in a limited-resource setting: A retrospective study from Botswana.

Elizabeth Corn, Kelly Becht, Bethel Adefres et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e17502

e17502 Background: Cervical cancer is the number one cause of cancer-related mortality for women in Botswana, the care of...

Nivolumab + ipilimumab (NIVO + IPI) vs NIVO in microsatellite instability high/mismatch repair-deficient metastatic colorectal cancer (MSI-H/dMMR mCRC): CheckMate 8HW subgroup analyses including treatment-free status and outcomes in long-term survivors.

Elena Elez, Thierry André, Sara Lonardi et al. Jun 01, 2026 pp. 3532-3532 10.1200/jco.2026.44.16_suppl.3532

3532 Background: In the phase 3 CheckMate 8HW trial, both dual primary endpoints of progression-free survival (PFS) were m...

The 31-gene expression profile for identification of real-world node-negative patients with stage I-IIA cutaneous melanoma who have a higher risk of death: A SEER collaboration.

J. Michael Guenther, Stanley P. L. Leong, Andrew Joseph Ward et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e21593

e21593 Background: Most patients with stage I-IIA (tumor stage T1-T3a) cutaneous melanoma (CM) have good overall outcomes,...

Condensate-driven transcriptional reprogramming to define core vulnerabilities in esophageal and gastric cancers.

Luis Alvarez, Alberto Ocaña, Andres Tejedor et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e15119

e15119 Background: Biomolecular condensates organize key nuclear functions through phase separation, yet their roles in ga...

Phase I trial of combination gemcitabine (gem) and nab-sirolimus (nab-S) in advanced leiomyosarcomas (LMS) or advanced soft-tissue sarcomas (STS) with <i>TSC1/2</i> alterations: Preliminary results.

Elise F. Nassif Haddad, Heather Y. Lin, Priya Bhosale et al. Jun 01, 2026 pp. 11578-11578 10.1200/jco.2026.44.16_suppl.11578

11578 Background: Advanced LMS has limited effective therapies, with gem-based regimens being the most prescribed. Preclin...

Phase 1 trial of a KRAS G12V/HLA-A*11:01–restricted TCR-engineered T-cell therapy in advanced solid tumors.

Ding Xiaoyan, Wen Zhang, Ying Teng et al. Jun 01, 2026 pp. 2542-2542 10.1200/jco.2026.44.16_suppl.2542

2542 Background: KRAS G12V is a prevalent oncogenic driver in solid tumors, particularly pancreatic cancer (PC), occurring...

Stratification of cardiovascular complications with immunotherapy.

Aditya Lakkamsani, Ronak S. Patel, Suhaib Hyder et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24004

e24004 Background: Immune checkpoint inhibitors (ICIs) are used to treat various malignancies and have expanded the therap...

HERTHENA-Breast04: A phase 3, randomized, open-label study evaluating the efficacy and safety of patritumab deruxtecan (HER3-DXd) versus treatment of physician’s choice in hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) unresectable locally advanced or metastatic breast cancer.

Barbara Pistilli, Surui Hou, Julie Marie Collins et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.tps1149

TPS1149 Background: There is an unmet therapeutic need for patients with HR+/HER2− metastatic breast cancer who experience...

Utility of sacubitril/valsartan in the prevention of cancer therapy–related cardiac dysfunction (CTRCD) in patients receiving cardiotoxic chemotherapy agents: A systematic review and meta-analysis.

Sreejith Vijayakumar, Venkata Sai Abhilash Meda, Anjani Mahesh Kumar Cherukuri et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e24038

e24038 Background: Cancer therapy–related cardiac dysfunction (CTRCD) is a recognized adverse effect of cardiotoxic chemot...

Efficacy and safety of intrathecal chemotherapy in <i>EGFR</i> -mutant non–small cell lung cancer with leptomeningeal metastases: A systematic review and meta-analysis.

Rishi Kumar Nanda, Daniel Thomas Jones, Kyaw Zin Thein et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e20700

e20700 Background: Leptomeningeal metastases (LM) are a particularly challenging complication of EGFR-mutant non–small cel...

Alcohol-related hospitalizations among patients with cancer in the United States: Trends and associated risk factors.

Anna Mehlich, Dawid Mehlich, Alexandra Sueldo et al. Jun 01, 2026 pp. 10624-10624 10.1200/jco.2026.44.16_suppl.10624

10624 Background: Alcohol consumption is associated with an increased risk of developing multiple cancers and has been lin...

Epidemiology of head and neck cancers in Syria: An analysis from the national oncology center.

Ahmad Al-Bitar, Fatima Al-Jojo, Ziyad Marawi et al. Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e18122

e18122 Background: Epidemiological data on head and neck cancers (HNC) in conflict-affected regions like Syria are scarce....

Impact of structured oncologist-led home visits on psychological distress and resilience in patients with solid tumors undergoing chemotherapy: A comparative study.

Sonya Kircheva Draganova, Radostina Gencheva, Mariyana Eneva et al. Jun 01, 2026 pp. 12089-12089 10.1200/jco.2026.44.16_suppl.12089

12089 Background: Psychological distress is prevalent among patients receiving chemotherapy. Home-based supportive interve...

Immune checkpoint inhibitors and molecular targeted agents with or without transarterial chemoembolization in unresectable hepatocellular carcinoma with first- or lower-order portal vein tumor thrombosis: A target trial emulation framework.

Lin Longwang Jun 01, 2026 10.1200/jco.2026.44.16_suppl.e16293

e16293 Background: The optimal treatment for unresectable hepatocellular carcinoma (HCC) complicated by portal vein tumor...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page